These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35970069)

  • 1. Diminishing hERG inhibitory activity of aminopiperidine-naphthyridine linked NBTI antibacterials by structural and physicochemical optimizations.
    Kokot M; Weiss M; Zdovc I; Anderluh M; Hrast M; Minovski N
    Bioorg Chem; 2022 Nov; 128():106087. PubMed ID: 35970069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure activity relationship of C-2 ether substituted 1,5-naphthyridine analogs of oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-5).
    Singh SB; Kaelin DE; Meinke PT; Wu J; Miesel L; Tan CM; Olsen DB; Lagrutta A; Fukuda H; Kishii R; Takei M; Takeuchi T; Takano H; Ohata K; Kurasaki H; Nishimura A; Shibata T; Fukuda Y
    Bioorg Med Chem Lett; 2015 Sep; 25(17):3630-5. PubMed ID: 26152426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bimodal Actions of a Naphthyridone/Aminopiperidine-Based Antibacterial That Targets Gyrase and Topoisomerase IV.
    Gibson EG; Oviatt AA; Cacho M; Neuman KC; Chan PF; Osheroff N
    Biochemistry; 2019 Nov; 58(44):4447-4455. PubMed ID: 31617352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amide containing NBTI antibacterials with reduced hERG inhibition, retained antimicrobial activity against gram-positive bacteria and in vivo efficacy.
    Kokot M; Weiss M; Zdovc I; Senerovic L; Radakovic N; Anderluh M; Minovski N; Hrast M
    Eur J Med Chem; 2023 Mar; 250():115160. PubMed ID: 36753879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tricyclic 1,5-naphthyridinone oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents-SAR of left-hand-side moiety (Part-2).
    Singh SB; Kaelin DE; Wu J; Miesel L; Tan CM; Black T; Nargund R; Meinke PT; Olsen DB; Lagrutta A; Lu J; Patel S; Rickert KW; Smith RF; Soisson S; Sherer E; Joyce LA; Wei C; Peng X; Wang X; Fukuda H; Kishii R; Takei M; Takano H; Shibasaki M; Yajima M; Nishimura A; Shibata T; Fukuda Y
    Bioorg Med Chem Lett; 2015 May; 25(9):1831-5. PubMed ID: 25851938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Structural Features of Novel Bacterial Topoisomerase Inhibitors That Define Their Activity on Topoisomerase IV.
    Kokot M; Anderluh M; Hrast M; Minovski N
    J Med Chem; 2022 May; 65(9):6431-6440. PubMed ID: 35503563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The overview of development of novel bacterial topoisomerase inhibitors effective against multidrug-resistant bacteria in an academic environment: From early hits to in vivo active antibacterials.
    Zorman M; Hrast Rambaher M; Kokot M; Minovski N; Anderluh M
    Eur J Pharm Sci; 2024 Jan; 192():106632. PubMed ID: 37949194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.
    Mitton-Fry MJ; Brickner SJ; Hamel JC; Barham R; Brennan L; Casavant JM; Ding X; Finegan S; Hardink J; Hoang T; Huband MD; Maloney M; Marfat A; McCurdy SP; McLeod D; Subramanyam C; Plotkin M; Reilly U; Schafer J; Stone GG; Uccello DP; Wisialowski T; Yoon K; Zaniewski R; Zook C
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3353-3358. PubMed ID: 28610977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure activity relationship of N-1 substituted 1,5-naphthyrid-2-one analogs of oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-9).
    Singh SB; Tan CM; Kaelin D; Meinke PT; Miesel L; Olsen DB; Fukuda H; Kishii R; Takei M; Ohata K; Takeuchi T; Shibue T; Takano H; Nishimura A; Fukuda Y
    Bioorg Med Chem Lett; 2022 Nov; 75():128808. PubMed ID: 35609741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxy tricyclic 1,5-naphthyridinone oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents-SAR of RHS moiety (Part-3).
    Singh SB; Kaelin DE; Wu J; Miesel L; Tan CM; Gill C; Black T; Nargund R; Meinke PT; Olsen DB; Lagrutta A; Wei C; Peng X; Wang X; Fukuda H; Kishii R; Takei M; Takeuchi T; Shibue T; Ohata K; Takano H; Ban S; Nishimura A; Fukuda Y
    Bioorg Med Chem Lett; 2015 Jun; 25(12):2473-8. PubMed ID: 25978963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vitro and In Vivo Characterization of the Novel Oxabicyclooctane-Linked Bacterial Topoisomerase Inhibitor AM-8722, a Selective, Potent Inhibitor of Bacterial DNA Gyrase.
    Tan CM; Gill CJ; Wu J; Toussaint N; Yin J; Tsuchiya T; Garlisi CG; Kaelin D; Meinke PT; Miesel L; Olsen DB; Lagrutta A; Fukuda H; Kishii R; Takei M; Oohata K; Takeuchi T; Shibue T; Takano H; Nishimura A; Fukuda Y; Singh SB
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4830-9. PubMed ID: 27246784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy.
    Dougherty TJ; Nayar A; Newman JV; Hopkins S; Stone GG; Johnstone M; Shapiro AB; Cronin M; Reck F; Ehmann DE
    Antimicrob Agents Chemother; 2014 May; 58(5):2657-64. PubMed ID: 24566174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of aminopiperidine based potent & novel topoisomerase inhibitor with broad spectrum anti-bacterial activity.
    Desai J; Patel B; Panchal N; Gite A; Darji B; Viswanathan K; Trivedi J; Vyas P; Pawar V; Giri P; S S; Sharma R; Jain M; Iyer P; Kumar S
    Bioorg Med Chem Lett; 2024 Oct; 111():129911. PubMed ID: 39067715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-generation 4,5,6,7-tetrahydrobenzo[
    Lamut A; Skok Ž; Barančoková M; Gutierrez LJ; Cruz CD; Tammela P; Draskovits G; Szili PÉ; Nyerges Á; Pál C; Molek P; Bratkovič T; Ilaš J; Zidar N; Zega A; Enriz RD; Kikelj D; Tomašič T
    Future Med Chem; 2020 Feb; 12(4):277-297. PubMed ID: 32043377
    [No Abstract]   [Full Text] [Related]  

  • 15. Discovery of substituted oxadiazoles as a novel scaffold for DNA gyrase inhibitors.
    Jakopin Ž; Ilaš J; Barančoková M; Brvar M; Tammela P; Sollner Dolenc M; Tomašič T; Kikelj D
    Eur J Med Chem; 2017 Apr; 130():171-184. PubMed ID: 28246042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and anti-staphylococcal activity of novel bacterial topoisomerase inhibitors with a 5-amino-1,3-dioxane linker moiety.
    Li L; Okumu A; Dellos-Nolan S; Li Z; Karmahapatra S; English A; Yalowich JC; Wozniak DJ; Mitton-Fry MJ
    Bioorg Med Chem Lett; 2018 Aug; 28(14):2477-2480. PubMed ID: 29871847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and antibacterial evaluation of new quinoline-1,3,4-oxadiazole and quinoline-1,2,4-triazole hybrids as potential inhibitors of DNA gyrase and topoisomerase IV.
    Hofny HA; Mohamed MFA; Gomaa HAM; Abdel-Aziz SA; Youssif BGM; El-Koussi NA; Aboraia AS
    Bioorg Chem; 2021 Jul; 112():104920. PubMed ID: 33910078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and Evaluation of N-Phenylpyrrolamides as DNA Gyrase B Inhibitors.
    Durcik M; Tammela P; Barančoková M; Tomašič T; Ilaš J; Kikelj D; Zidar N
    ChemMedChem; 2018 Jan; 13(2):186-198. PubMed ID: 29206345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), Part II: development of inhibitors with broad spectrum, Gram-negative antibacterial activity.
    Trzoss M; Bensen DC; Li X; Chen Z; Lam T; Zhang J; Creighton CJ; Cunningham ML; Kwan B; Stidham M; Nelson K; Brown-Driver V; Castellano A; Shaw KJ; Lightstone FC; Wong SE; Nguyen TB; Finn J; Tari LW
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1537-43. PubMed ID: 23294697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclohexyl amide-based novel bacterial topoisomerase inhibitors with prospective GyrA-binding fragments.
    Kolarič A; Novak D; Weiss M; Hrast M; Zdovc I; Anderluh M; Minovski N
    Future Med Chem; 2019 May; 11(9):935-945. PubMed ID: 31140866
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.